

1  
B  
adding one or more amino acids without changing the three dimensional configuration thereof.

- B 2
12. (Twice Amended) A pharmaceutical composition comprising:  
an antibody according to claim 1 and  
a suitable carrier.

Please add new claims 20-31 as follow:

Sub-D1  
3  
B  
20. (New) The antibody according to claim 2, wherein the C-terminal part comprises a region of the prion protein ranging from amino acid no. 202 to amino acid no. 214 or to variants obtained by substituting or omitting or adding one or more amino acids without changing the three dimensional configuration thereof.

~~21. (New) A method of immunizing against Bovine Spongiform Encephalopathy, Creutzfeld-Jacobs-Disease, a variant form of Creutzfeld-Jacobs-Disease or Transmissible Spongiform Encephalopathy related diseases comprising:  
administering to an individual an effective amount of the anti-idiotypic antibody according to claim 15.~~

~~22. (New) A method of immunizing against Bovine Spongiform Encephalopathy, Creutzfeld-Jacobs-Disease, a variant form of Creutzfeld-Jacobs-Disease or Transmissible Spongiform Encephalopathy related diseases comprising:  
administering to an individual an effective amount of the peptide according to claim 17.~~

~~23. (New) A method of immunizing against Bovine Spongiform Encephalopathy, Creutzfeld-Jacobs-Disease, a variant form of Creutzfeld-Jacobs-Disease or Transmissible Spongiform Encephalopathy related diseases comprising:~~

~~administering to an individual an effective amount of the peptide  
according to claim 18.~~

Sub D17  
B  
24. (New) A method of diagnosing Bovine Spongiform Encephalopathy, Creutzfeld-Jacobs-Disease, a variant form of Creutzfeld-Jacobs-Disease or Transmissible Spongiform Encephalopathy related diseases comprising:

contacting a specimen with the antibody of claim 1 or a functional part thereof under immunological reaction conditions; and  
detecting any immunological binding between the specimen and the antibody.

25. A method of treating Bovine Spongiform Encephalopathy, Creutzfeld-Jacobs-Disease, a variant form of Creutzfeld-Jacobs-Disease or Transmissible Spongiform Encephalopathy related diseases, said method comprising:

producing the antibody according to claim 1; and  
injecting said antibody into individuals in an amount effective to provide an immune response to the infectious agent of Bovine Spongiform Encephalopathy, Creutzfeld-Jacobs-Disease, a variant form of Creutzfeld-Jacobs-Disease and Transmissible Spongiform Encephalopathy related diseases.

26. (New) A kit for the diagnosis of Bovine Spongiform Encephalopathy, Creutzfeld-Jacobs-Disease, a variant form of Creutzfeld-Jacobs-Disease or Transmissible Spongiform Encephalopathy related diseases, said kit comprising:

an antibody according to claim 1, wherein the antibody binds under immunological conditions to a biological sample of an individual infected with Bovine Spongiform Encephalopathy, Creutzfeld-Jacobs-Disease, a variant form of Creutzfeld-Jacobs-Disease or a Transmissible Spongiform Encephalopathy related disease.

27. (New) A kit according to claim 26, further comprising:

a solid support material,  
buffers, and  
markers for detection of any immunological binding of the antibody in  
a biological sample.

3  
28. ~~(New) A kit for immunizing individuals against Bovine Spongiform Encephalopathy, Creutzfeld-Jacobs-Disease, a variant form of Creutzfeld-Jacobs-Disease or Transmissible Spongiform Encephalopathy related diseases, said kit comprising:~~

~~the anti-idiotypic antibody according to claim 15 and  
a carrier suitable for administration to an individual.~~

29. ~~(New) A kit for immunizing individuals against Bovine Spongiform Encephalopathy, Creutzfeld-Jacobs-Disease, a variant form of Creutzfeld-Jacobs-Disease or Transmissible Spongiform Encephalopathy related diseases, said kit comprising:~~

~~a peptide according to claim 17, and  
a carrier suitable for administration to an individual.~~

Sub D1  
30. ~~(New) A kit for immunizing individuals against Bovine Spongiform Encephalopathy, Creutzfeld-Jacobs-Disease, a variant form of Creutzfeld-Jacobs-Disease or Transmissible Spongiform Encephalopathy related diseases, said kit comprising:~~

~~a peptide according to claim 18, and  
a carrier suitable for administration to an individual.~~


31. (New) A kit for treating individuals against Bovine Spongiform Encephalopathy, Creutzfeld-Jacobs-Disease, a variant form of Creutzfeld-Jacobs-Disease or Transmissible Spongiform Encephalopathy related diseases, said kit comprising:

an antibody according to claim 1 and  
a carrier suitable for administration to an individual.

Pursuant to 37 C.F.R. § 1.121, the marked-up version of the above amendment to claims 1-2 and 12 is appended hereto as Appendix A.

Respectfully submitted,

Date: February 21, 2001



Michael L. Goldman  
Registration No. 30,727

NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603  
Telephone: (716) 263-1304  
Facsimile: (716) 263-1600

Certificate of Mailing - 37 CFR 1.8(a)	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents and Trademarks, Washington, D.C 20231 on the date below.	
2/13/01	Jo Ann Whalen
Date	Jo Ann Whalen